Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Annette S Kim"'
Autor:
Zihni Onur Çalışkaner, Türkan Çakar, Emrah Özçelik, Ahmet Özdilek, Annette S Kim, Öner Doğan, Amma Bosompem, Gerard Grosveld, Bülent Saka, Ayten Kandilci
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0178025 (2017)
Overexpression of DEK oncogene is associated with increased proliferation of carcinoma cells and it is observed in several solid tumors due to the amplification of the 6p22.3 chromosomal region where DEK locates. Although the same chromosomal amplifi
Externí odkaz:
https://doaj.org/article/95856b20c4854a819afceeeeebc01fda
Autor:
Max A. Stockslager, Seth Malinowski, Mehdi Touat, Jennifer C. Yoon, Jack Geduldig, Mahnoor Mirza, Annette S. Kim, Patrick Y. Wen, Kin-Hoe Chow, Keith L. Ligon, Scott R. Manalis
Publikováno v:
Cell Reports, Vol 37, Iss 1, Pp 109788- (2021)
Summary: Functional precision medicine aims to match individual cancer patients to optimal treatment through ex vivo drug susceptibility testing on patient-derived cells. However, few functional diagnostic assays have been validated against patient o
Externí odkaz:
https://doaj.org/article/e91ca42247b7413da4ad84cd61fab80b
Autor:
Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Publikováno v:
Blood Advances. 7:1929-1943
Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has been complicated by the development of resistance. The most common resistance mechanism in patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8383f4c725051ef015310abdc3f2d39
https://doi.org/10.1182/bloodadvances.2022008447
https://doi.org/10.1182/bloodadvances.2022008447
Autor:
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Zachariah DeFilipp, Areej El-Jawahri, Steve L. McAfee, Andrew M. Brunner, Philip C. Amrein, Alice S. Mims, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Dylan M. Marchione, Vincent T. Ho, Yi-Bin Chen
Publikováno v:
Clinical Cancer Research. 29:2034-2042
Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML. Patients and Methods: We conducted a multicent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6018d58039b44e1e6368f3333c96f2a6
https://doi.org/10.1158/1078-0432.ccr-23-0182
https://doi.org/10.1158/1078-0432.ccr-23-0182
Autor:
Benjamin L. Lampson, Aditi Gupta, Svitlana Tyekucheva, Kiyomi Mashima, Anna Petráčková, Zixu Wang, Natalia Wojciechowska, Conner J. Shaughnessy, Peter O. Baker, Stacey M. Fernandes, Samantha Shupe, John-Hanson Machado, Rayan Fardoun, Annette S. Kim, Jennifer R. Brown
Publikováno v:
Journal of Clinical Oncology. 41:1116-1128
PURPOSE Germline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing. The ataxia telangiectasia–mutated ( ATM) gene on chromosome 11 has more than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c834bcfab54c576b3ae2d84bf3e046b
https://doi.org/10.1200/jco.22.00269
https://doi.org/10.1200/jco.22.00269
Autor:
Peter G. Miller, Geoffrey G. Fell, Brody H. Foy, Allison K. Scherer, Christopher J. Gibson, Adam S. Sperling, Bala B. Burugula, Tetsushi Nakao, Md M. Uddin, Hailey Warren, Lynn Bry, Olga Pozdnyakova, Matthew J. Frigault, Alex G. Bick, Donna Neuberg, John M. Higgins, Michael K. Mansour, Pradeep Natarajan, Annette S. Kim, Jacob O. Kitzman, Benjamin L. Ebert
Publikováno v:
Blood. 140:1993-1997
Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc5f01e34603d8e57272f12ccd2fabc
https://doi.org/10.1182/blood.2022018052
https://doi.org/10.1182/blood.2022018052
Autor:
Christopher B. Hergott, Annette S. Kim
Publikováno v:
Clinics in Laboratory Medicine. 42:325-347
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2065752159d666754a22b6340fc45c01
https://doi.org/10.1016/j.cll.2022.04.005
https://doi.org/10.1016/j.cll.2022.04.005
Autor:
Harrison K. Tsai, Christopher J. Gibson, H. Moses Murdock, Phani Davineni, Marian H. Harris, Eunice S. Wang, Lukasz P. Gondek, Annette S. Kim, Valentina Nardi, R. Coleman Lindsley
Publikováno v:
Blood Advances. 6:4236-4240
KMT2A partial tandem duplication (KMT2A-PTD) is an adverse risk factor in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a potential therapeutic target, and an attractive marker of measurable residual disease. High initial KMT2A-PTD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283bcbe5c294151c638d927419e2e4d2
https://doi.org/10.1182/bloodadvances.2022007613
https://doi.org/10.1182/bloodadvances.2022007613
Autor:
Thomas D. Lee, Dara L. Aisner, Marjorie Parker David, Celeste C. Eno, Jeffrey Gagan, Christopher D. Gocke, Natalya V. Guseva, Lisa Haley, Audrey N. Jajosky, Daniel Jones, Mahesh M. Mansukhani, Pawel Mroz, Sarah S. Murray, Kimberly J. Newsom, Vera Ashley Paulson, Somak Roy, Chase Rushton, Jeremy P. Segal, T. Niroshini Senaratne, Alexa J. Siddon, Petr Starostik, Jessica A. G. Van Ziffle, David Wu, Rena R. Xian, Sophia Yohe, Annette S. Kim
Publikováno v:
Blood Advances.
While molecular testing of hematologic malignancies is now standard of care, there is variability in practice and testing capabilities between different academic laboratories, with common questions arising on how to best meet clinical expectations. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::466997e7f0665dda7f860d141b300963
https://doi.org/10.1182/bloodadvances.2023010149
https://doi.org/10.1182/bloodadvances.2023010149
Autor:
Yi-Bin Chen, Vincent T. Ho, Dylan M. Marchione, Elayne Breton, Jennifer Brock, Jonathan L. Wahl, Lindsey H. Perry, AJ S. Bottoms, Devon Kelley, Laura W. Knight, Alice S. Mims, Philip C. Amrein, Andrew M. Brunner, Steve L. McAfee, Areej El-Jawahri, Zachariah DeFilipp, Annette S. Kim, Shuli Li, Mark J. Levis, Robert J. Soiffer, Haesook T. Kim, Amir T. Fathi
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41242f9d5f686fdbc7c3a194abe99cc1
https://doi.org/10.1158/1078-0432.22651561.v1
https://doi.org/10.1158/1078-0432.22651561.v1
